Literature DB >> 18758491

Twisted epithelial-mesenchymal transition blocks senescence.

Robert A Weinberg1.   

Abstract

The epithelial-mesenchymal transition (EMT) is a cellular transdifferentiation program that enables epithelial cancer cells to acquire traits of high-grade malignancy, notably invasive and metastatic powers. A new study indicates that it may also function early in tumour progression by preventing oncogene-induced senescence.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18758491     DOI： 10.1038/ncb0908-1021

Source DB:  PubMed          Journal:  Nat Cell Biol        ISSN： 1465-7392            Impact factor:   28.824


  32 in total

1.  How apoptosis and epithelial-to-mesenchymal transition are nested in EGFR inhibitors resistance in lung cancer.

Authors:  Simon Garinet; Audrey Didelot; Elena Garelli; Karine Pallier; Hélène Blons; Antoine Legras
Journal:  J Thorac Dis       Date:  2019-01       Impact factor: 2.895

2.  PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures.

Authors:  Minyoung Lim; Cheng-Ming Chuong; Pradip Roy-Burman
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

3.  The 3D tissue microenvironment modulates DNA methylation and E-cadherin expression in squamous cell carcinoma.

Authors:  Teresa M DesRochers; Yulia Shamis; Addy Alt-Holland; Yasusei Kudo; Takashi Takata; Guangwen Wang; Laurie Jackson-Grusby; Jonathan A Garlick
Journal:  Epigenetics       Date:  2012-01-01       Impact factor: 4.528

4.  Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers.

Authors:  Andrew J Armstrong; Matthew S Marengo; Sebastian Oltean; Gabor Kemeny; Rhonda L Bitting; James D Turnbull; Christina I Herold; Paul K Marcom; Daniel J George; Mariano A Garcia-Blanco
Journal:  Mol Cancer Res       Date:  2011-06-10       Impact factor: 5.852

5.  Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.

Authors:  Alejandro Vazquez-Martin; Eugeni López-Bonetc; Sílvia Cufí; Cristina Oliveras-Ferraros; Sonia Del Barco; Begoña Martin-Castillo; Javier A Menendez
Journal:  Drug Resist Updat       Date:  2011-05-19       Impact factor: 18.500

6.  Simvastatin prevents skeletal metastasis of breast cancer by an antagonistic interplay between p53 and CD44.

Authors:  Chandi Charan Mandal; Nayana Ghosh-Choudhury; Toshi Yoneda; Goutam Ghosh Choudhury; Nandini Ghosh-Choudhury
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

7.  Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths.

Authors:  Marjon A Smit; Daniel S Peeper
Journal:  Aging (Albany NY)       Date:  2010-10       Impact factor: 5.682

Review 8.  Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.

Authors:  Aiko Nagayama; Leif W Ellisen; Bruce Chabner; Aditya Bardia
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

9.  Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses.

Authors:  Robert Strauss; Pavel Sova; Ying Liu; Zong Yi Li; Sebastian Tuve; David Pritchard; Paul Brinkkoetter; Thomas Möller; Oliver Wildner; Sari Pesonen; Akseli Hemminki; Nicole Urban; Charles Drescher; André Lieber
Journal:  Cancer Res       Date:  2009-06-02       Impact factor: 12.701

10.  Notch3 is important for TGF-β-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1.

Authors:  L Liu; X Chen; Y Wang; Z Qu; Q Lu; J Zhao; X Yan; H Zhang; Y Zhou
Journal:  Cancer Gene Ther       Date:  2014-08-01       Impact factor: 5.987
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.